Source: Annual Congress 2009 - Treatment of lung cancer
Disease area: Thoracic oncology

Abstract

Detection of various mutations of growth factors genes of tumor is one of the most important aims in research.
The purpose of the study is to estimate the clinical significance of mutant gene EGFR evaluation in pts with adenocarcinoma lung cancer.
Material and methods: Tumor samples have been obtained from 47 pts with adenocarcinoma via biopsy and/or surgical operation.
The direct tumor DNA sequence of exons 18-21 EGFR gene has been performed. Del19EGFR and mutation L858R were revealed. The mutant gene del19EGFR has been detected by PCR in 14 pts (29,8%), mutation L858R – in 1 pt (4,7%).
All pts have received EGFR tyrosin-kinase inhibitor - gefitinib. The overall response was estimated by RECIST. The analysis of 24-month survival formed 86%, pts have positive mutation gene EGFR – del19EGFR (see Figure 1) and best response (complete response partial response and stable disease) was observed in both groups (47.9% in pts with negative mutation gene EGFR vs 53.0% in pt with positive mutation gene EGFR).

Conclusion: The detection of mutant gene EGFR (del19EGFR) appears to be a prognostic factor. Administration of EGFR tyrosin-kinase inhibitor in pts with adenocarcinoma is clinically effective in pts with negative gene EGFR mutation. These findings should be analyzed later on.

Rating:

Share or cite this content

Citations should be made in the following way:
L. Stelmakh, S. Orlov, I. Dvorakovskaya (St-Petersburg, Russian Federation). Survival prognosis and target therapy best response in adenocarcinoma lung cancer pts with mutation EGFR gene. Eur Respir J 2009; 34: Suppl. 53, 2658

Member's Comments

No comment yet.

Related content which might interest you: A variant in LKB1 gene can predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018 Her/2 neu and p53 expression in patients with non-small cell lung cancer predict shortened survival Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation Source: Eur Respir J 2011; 37: 624-631 Year: 2011 Clinical relevance of p53 and K-ras gene mutations in bronchial margins in surgically treated nonsmall cell lung cancer (NSCLC) patients Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002 MDM-2 gene amplification is associated with poor prognosis in operable non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 596s Year: 2002 ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer Year: 2009 Tumor specific MUC1 expression in operable lung cancer correlates with improved survival Source: Eur Respir J 2005; 26: Suppl. 49, 459s Year: 2005 Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011 Characteristics and prognostic relevance of p53 gene mutations in Polish non small cell lung cancer (NSCLC) patients Source: Eur Respir J 2005; 26: Suppl. 49, 92s Year: 2005 p-53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer Source: Annual Congress 2007 - Novel genetic markers in pathology Year: 2007 Overall survival analysis and characterization of an EGFR mutated non small cell lung cancer (NSCLC) population Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017 p53 mutations do not predict response to paclitaxel in metastatic non-small cell lung carcinoma Source: Annual Congress 2009 - Lung cancer biology Year: 2009 TTF-1 for prediction of response to chemotherapy in patients with locally advanced or metastatic small cell lung cancer (SCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Prognosis of uncommon metastasis in non-small-cell lung cancer patients with mutated EGFR Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 Survival outcomes of non small cell lung cancer (NSCLC) patients who are suitable for radical treatment at initial presentation Source: Annual Congress 2011 - Quality management for lung cancer patients Year: 2011 Fascin-1 overexpression predicts a poor prognosis in non-small cell lung cancer Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 Model for predicting EGFR mutation status in lung cancer Source: Breathe, 15 (4) 340; 10.1183/20734735.0250-2019 Year: 2019 Is Cyfra 21-1 serum level predictive for the type of response to treatment or survival in locally advanced and metastatic non-small cell lung cancer (NSCLC)? Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004 Frequency of T790M substitution in exon 20 of EGFR gene in brain metastases in chemotherapy-naive non-small cell lung cancer patients (NSCLC) Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease Year: 2012 Survival outcomes of patients diagnosed with lung adenocarcinoma with ALK gene rearrangement Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021